FELMETATUG VEDOTIN
UNII VG5Y3A9DFS

Substance Identification & Data

This profile provides standardized clinical and technical data for Felmetatug Vedotin, uniquely identified by the FDA Unique Ingredient Identifier (UNII) VG5Y3A9DFS.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2924808-30-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

VG5Y3A9DFS

CAS Registry Number

2924808-30-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

FELMETATUG VEDOTIN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C186669

National Cancer Institute reference terminology for clinical and research data.

INN ID

13231

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Felmetatug Vedotin

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Felmetatug Vedotin. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Felmetatug Vedotin

Common Names & Synonyms

Felmetatug vedotin [WHO-DD]

H-gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV4-39*01 (96.0%) -(IGHD) -IGHJ5*02 (93.8%), CDR-IMGT [10.7.12] (26-35.53-59.98-109)) (1-120) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-15*01 (96.8%) -IGKJ4*01 (91.7%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, glycoform alfa; substituted at the sulfur atoms of four L-cysteinyl residues on an average among 223, 229, 232, 214', 223'', 229'', 232'' and 214''' with a group consisting of (3RS)-1-(6-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(2S)-1-{[(2S)-1-{[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl](methyl)carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl (vedotin)

Immunoglobulin G1, anti-(human/Macaca fascicularis/Mus musculus B7 homolog protein B7H4) (human monoclonal B7H41001 γ1-chain), disulfide with human monoclonal B7H41001 κ-chain, dimer, reduced, tetrakis(thioether) with N-[[[4-[[N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide

felmetatug vedotin [INN]

immunoglobulin G1-kappa, anti-[Homo sapiens VTCN1 (V-set domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)], Homo sapiens monoclonal antibody, conjugated on an average of four cysteinyl residues to vedotin, comprising a cleavable linker and monomethylauristatin E (MMAE);

External Clinical & Regulatory Resources

Previous UNIIVG5TWB4MMS

Next UNIIVG66T9P4K2